Synopsis

Source of validity: Scientific
Rating (out of 5): 3

San-Qi Ginseng, also known as Panax notoginseng, has a long history of use in Traditional Chinese Medicine (TCM) for cardiovascular health, particularly for stopping bleeding and promoting blood circulation. More recently, modern scientific research has investigated its effects on cardiovascular disease (CVD). The main active constituents, notoginsenosides and saponins, have demonstrated multiple cardioprotective actions in preclinical studies. These include anti-inflammatory, anti-platelet aggregation, anti-oxidative, and lipid-lowering effects, as well as improvement of endothelial function and protection against ischemia-reperfusion injury.

A number of animal and in vitro studies have shown that San-Qi Ginseng can reduce the size of myocardial infarction, decrease blood pressure, improve blood lipid profiles, and inhibit thrombosis. Small clinical trials and meta-analyses, mainly conducted in China, suggest potential benefits for patients with coronary heart disease and angina, including improvement in symptoms and some biomarkers of cardiovascular risk. However, the quality of clinical evidence is variable, with many studies lacking rigorous controls or having small sample sizes. No large-scale, high-quality randomized controlled trials have definitively established its efficacy in humans.

Overall, the use of San-Qi Ginseng for cardiovascular health is supported by a combination of traditional use and a growing body of scientific evidence, particularly from preclinical studies. The clinical evidence is promising but not yet conclusive, warranting a moderate evidence rating.

More about San-Qi Ginseng
More about Cardiovascular Disease

Other ingredients used for Cardiovascular Disease

Other health conditions supported by San-Qi Ginseng

Products containing San-Qi Ginseng